D. Corey

Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia

This study identifies TIM-4-L as a novel target for T cell therapy in AML, showing engineered T cells effectively eliminate AML cells in vitro and in vivo.

Novel engineered chimeric engulfment receptors trigger T-cell effector functions against SIV infected CD4+ T cells

This study shows that engineered T cells with chimeric engulfment receptors can kill SIV-infected CD4+ T cells by recognizing phosphatidylserine.